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CObjectives: To quantify the trade-offs of alternative strategies in treat-
ing pediatricmajor depressive disorderwith respect to the clinical ben-
efit and risk of fatal and nonfatal suicidal behavior over a 5-year time
horizon.Methods: Wedeveloped a disease simulationmodel integrat-
ing epidemiological and clinical data from the literature to simulate the
effect of selective serotonin reuptake inhibitors (SSRIs), cognitive be-
havioral therapy (CBT), and a combination of both on a US pediatric
population with major depressive disorder. Results: In a cohort of
,000,000 simulated individuals (ages 10–24 years), the use of SSRIswas
ssociated with the highest number of suicide-related events, while
BT was associated with the lowest number. Over a 5-year period, the O
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http://dx.doi.org/10.1016/j.jval.2012.03.1390trategywith the highest number of symptom-freeweeks depended on
ssumptions made regarding treatment efficacy beyond the available
linical data. Conclusions: Considering the risk-benefit profile over a
-year period, CBT offers a safer profile than combination treatment or
SRIs alone with respect to suicide deaths and attempts. Any addi-
ional benefits of SSRIs, either alone or in combination with CBT, must
e weighed against the expected increase in suicides.
eywords: adolescents, depression, disease simulation model, suicide,
reatment.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Since October 2004, antidepressants have carried a black-box
warning indicating an increased risk of suicidal ideation and be-
havior in children and adolescents. These warnings are based on
results from the US Food and Drug Administration (FDA) meta-
analyses of placebo-controlled randomized controlled trials
(RCTs) of antidepressants among children and adolescents, which
found an approximate twofold increase in the risk of suicidal ide-
ation and behavior among children and adolescents randomized
to antidepressants (4%) compared with placebo (2%) [1]. In 2007,
the warning was extended to young adults aged 18 to 24 years,
based on a reexamination of age-related trend data from the FDA
meta-analysis [2].
A more recent meta-analysis, which included two additional
RCTs, found that the risk of suicidal thinking and behavior among
pediatric patients with major depressive disorder (MDD) on anti-
depressants was increased significantly under model specifica-
tions used in the FDA meta-analysis (i.e., fixed effects models),
relative risk (RR)  1.9 (1.2–2.9), but not under different model
pecifications (i.e., random effects models), RR  1.6 (1.0–2.7) [3].
he authors concluded that the overall benefits of antidepressant
se in this population outweighed the risks. Because this study
as confined to information from placebo-controlled RCTs, it was
nable to examine the trade-off of risks and benefits under condi-
ions in which the alternative to antidepressant treatment was
nything other than placebo, such as cognitive behavioral therapy
* Address correspondence to:Djøra I. Soeteman, Center for Health
2nd Fl, Boston, MA 02115.
E-mail: dsoetema@hsph.harvard.edu.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.CBT) and combination treatments. In addition, the meta-analysis
ould not address how the overall benefits and risks of antidepres-
ant treatment extended over longer time horizons, because the
ncluded RCTs were of short duration (8–12 weeks).
Under conditions of uncertainty, decision-analytic methods
ave been used to extrapolate short-term effects observed in em-
irical studies to project longer-term health outcomes under dif-
erent “what-if” scenarios. Using such an approach, the current
tudy complements prior analyses of depression treatment for
hildren and young adults by incorporating empirical evidence
rom clinical studies in a disease simulation model to compare
hree treatment strategies (selective serotonin reuptake inhibitors
SSRIs], CBT, and a combination of SSRIs and CBT) in terms of
ymptom-free weeks and suicidality over a 5-year time horizon.
hemain focus of the studywas to explicitly describe the trade-off
n risks and benefits associated with these three competing strat-
gies and to examine the influence of plausible yet empirically
ncertain assumptions regarding suicide attempt risks and pa-
ients’ response to treatment.
Methods
Model
We developed a discrete event simulation (DES) model (TreeAge
Pro 2008, Williamstown, MA) integrating empirical data on the
ion Science, Harvard School of Public Health, 718 Huntington Ave,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
725V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 4 – 7 2 9natural history of depression and clinical effects of treatments
from the published literature to simulate a real-world population
of children and young adults with a clinical diagnosis of MDD. We
assumed a 5-year analytic time horizon; although MDD events
manifest over a longer time horizon, we elected a conservative
time frame of 5 years given the short duration of the clinical trial
data on clinical effects and risks of treatments. Unlike many
decision-analytic models that follow an entire cohort simulta-
neously over time (e.g., Markov), the DES approach simulates
individual patients one at a time, allowing for consideration of
important patient-specific sociodemographic characteristics
and individual variation of disease history [4]. Importantly, the
DES method relaxes the fixed time assumption that is charac-
teristic of Markov models, allowing for reflection of time to
event that may vary from patient to patient, either stochasti-
cally or because of an individual’s history. The model is then
used to estimate the impact of different interventions on the
average patient population.
The schematic of the DES model is shown in Figure 1. The
competing events that are possible during the simulation include
the following: 1) occurrence of a major depressive episode, 2) full
symptom relief, 3) partial symptom relief, 4) suicide attempt, 5)
suicide death, and 6) death from other causes (age- and sex-spe-
cific). At the start of the analysis, an individual with a major de-
pressive episode enters the model and is assigned a starting age
(ranging from 10 to 24 years) and sex from a distribution. The
major depressive episode can result in one of four events: full
symptom relief, partial symptom relief, suicide attempt, or death.
The order and timing of events are governed by time-to-event data
from survival distributions for each possible event [5]; once a new
event occurs, the time elapsed is noted and the age of the patient
is updated. If the patient experiences full symptom relief (i.e., Chil-
dren’s Depression Rating Scale-Revised score of 28 or less), the
competing events that may occur are recurrent depressive epi-
sode, suicide attempt, or death. Partial symptom relief is experi-
enced by those who respond to treatment but fail to remit in a
given MDD episode (i.e., an improvement score of 1 [very much
improved] or 2 [much improved] on the Clinical Global Impres-
sions-Improvement and a Children’s Depression Rating Scale-
Revised score of 29 or more) [6]; during partial symptom relief,
the competing events that are possible include relapse into a
depressive episode, suicide attempt, and death. A suicide at-
tempt can either be a fatal event or a nonfatal event. In the
event of a nonfatal suicide attempt, we assumed that patients
returned to the health status they were experiencing at the time
of the attempt.
To achieve convergence in model outcomes, a population of
1,000,000 patients was simulated for each treatment strategy, and
SSRIs
CBT
COMB
EpisodeEntry
 Pediatric 
population 
(ages 10-24) 
with MDD
Fig. 1 – Discrete eventhe history of events for each patient was tracked over a 5-yearperiod and aggregated. Model outcomes included symptom-free
weeks and numbers of both fatal and nonfatal suicidal acts. The
symptom-freeweekswere estimated as the duration of time spent
with no symptoms (i.e., in full symptom relief).
Data and assumptions
Natural history
The age and sex distribution shown in Table 1 was based on data
from the Sequenced Treatment Alternatives to Relieve Depression
study, which reported the age of onset of the study participants’
firstmajor depressive episode, ranging from childhood onset (ages
12 years) to late adult onset (ages 60 years) [7]. According to
evidence in the literature that women are twice as likely to be
depressed compared with men and that this sex gap emerges by
age 14 years, we applied a male/female ratio in depression of 1:1
for children aged 10 to 13 years and a ratio of 1:2 for children and
young adults aged 14 to 24 years [8].
We used survival distributions conditional on an individual’s
current age and past events to inform time to events (Table 2).
Natural history data on episode duration were obtained from a
Canadian study of individuals (ages 15 years or older) experiencing
a first depressive episode [9]. Time to recurrence of an episode for
individuals experiencing full symptom relief was influenced by
two factors: 1) duration of time without symptoms, such that the
risk of recurrence decreased with longer duration of full symptom
relief, and 2) number of previous depressive episodes, such that
the risk of recurrence increased (by 16%) with each successive
episode [15]. For those individuals experiencing partial symptom
relief, we calculated an increased risk of relapse of 48%, based on
the probability of relapse in the presence of residual symptoms
versus the absence of residual symptoms in the placebo arm of an
RCT [16].
General population data on fatal and nonfatal suicidal acts,
stratified by age and sex, were obtained from the Centers for Dis-
Partial symptom relief 
Full symptom relief
Suicide attempt
If the attempt is 
non-fatal, patients 
return to the 
original health 
status they were 
experiencing at 
the time of the 
attempt.
Death
ulation schematic.
Table 1 – Age and sex percentage distribution used in
the model [7].
Age (y) Male Female
10–12 9.32 9.32
13–15 9.07 18.14
16–18 8.70 17.40
19–21 7.08 14.17
22–24 2.27 4.53t simTotal 36.44 63.56
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726 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 4 – 7 2 9ease Control and Prevention [11] for years 2001 to 2006. A recent
study found that the risk of suicide attempts varied depending on
the level of depression, with the likelihood being nearly eightfold
higher during major depressive episodes and fourfold higher dur-
ing partial remission compared with that during full remission
[17]. We therefore assumed hazard ratios of suicide attempts of
7.74 during an episode and 4.20 during partial symptom relief in
the base-case analysis but also explored the impact of varying
these assumptions. Each patient was subject to background, all-
cause mortality based on the 2004 US life tables [14].
Treatment-related benefits
We evaluated three treatment strategies on the basis of clinical
guidelines for treating children and adolescents with MDD in the
United States: SSRIs, CBT, and combined SSRIs andCBT [18]. Treat-
ment efficacy was modeled as reductions in time to full symptom
relief and partial symptom relief from a depressive episode and
was, for the first 36 weeks after initiating therapy, based on remis-
sion rates reported from the Treatment for Adolescents with De-
pression Study (TADS) [10]. The proportion of patients who had
not achieved remission at the end of the 36weeks of the TADSwas
45% for patients treated with SSRIs, 36% for those treated with
CBT, and 40% for those treated with combination treatment. We
assumed that the rates of remission remained constant over time
for each treatment cohort and estimated the points in time at
which all patients were remitted by exponential extrapolation of
the existing data for each of the three treatment arms (see Figure
2 in Appendix A of Supplemental Materials found at http://dx.doi.
rg/10.1016/j.jval.2012.03.1390). We calculated the parameter of
he exponential model by using the probabilities observed at 36
eeks (panel A) but also explored the impact of an alternative
pproach (panel B). These population-based distributions were
sed to randomly draw individually based probabilities of time to
emission for each treatment arm.
Among all responders to treatment in the TADS, 44.4% remit-
ed and 55.6% failed to remit after 12 weeks of treatment [19]. We
ranslated this increased risk of responsewithout remission into a
5% reduction in time to partial symptom relief comparedwith full
ymptom relief for all treatment groups, but we varied this RR in
Table 2 – Summary of the data and distributions used in th
Event Sample time to event
Episode Full symptom relief
Partial symptom relief
Suicide attempt
Death
Partial symptom relief Episode
Suicide attempt
Death
Full symptom relief Episode
Suicide attempt
Death
Suicide attempt Suicide death
Note. Figures 1 to 5 in Appendix A of Supplemental Materials display
CDC, Centers for Disease Control and Prevention; SSRIs, selective s
combination.ensitivity analyses.Treatment-related suicide attempt risks
We assumed an elevated risk of suicide attempts of 70% associated
with SSRI treatment on the basis of a meta-analysis of placebo-con-
trolled trial data submitted to the Committee on Safety inMedicines
in theUnitedKingdom [12], inwhich suicide attempts in youthswith
depression were 70% more frequent among SSRI users than among
users of placebo. This estimate is very similar to the FDAmeta-anal-
ysis RR of 1.6 reported in the article by Bridge et al. [3]. By using this
information, coupled with the TADS data on the RRs of suicidal
events among users of SSRIs versus CBT versus combination treat-
ment, we generated population-based estimates of suicide attempt
rates for CBT and combination treatment: 35%decrease in the risk of
suicide attempts for CBT and 11% decrease in the risk of suicide at-
tempts for combination treatment relative to placebo [13].
Analysis
All patients begin the model in a major depressive episode and
initiate one of the three treatment strategies evaluated. In model-
ing the course of disease of an individual patient, we established
the temporal order and exact timing of events. For each competing
event, a randomnumber between 0 and 1 is drawn from a uniform
distribution. The inverse of the survival distribution is applied to
this random number to give the age at which the current event is
terminated. Subtracting the patient’s current age from this age of
termination yields the time to that particular event. From the sam-
pled times, the event with the earliest time occurs next and the
other times are discarded. This process is repeated after the oc-
currence of each new nonfatal event (i.e., remission to full or par-
tial symptom relief, nonfatal suicide attempt, recurrence or re-
lapse of depressive episode). By this approach, the sequence of
events experienced by the patient is randomly generated accord-
ing to the distributions assigned in the model. The simulation
ends when the patient dies from suicide or other causes or the
total time elapsed equals or exceeds the analytic time horizon of 5
years. This process was replicated for 1,000,000 patients per treat-
ment cohort, and the outcomes, including symptom-free weeks
and both fatal and nonfatal suicide attempts, were averaged
across age and sex subgroups.
First (scenario 1), we assessed the internal consistency of the
odel.
ural history distributions Treatment effect
Patten [9] Kennard et al. [10]
Patten [9] Kennard et al. [10]
CDC [11] SSRIs: Dubicka et al. [12]
CBT: The TADS Team [13]
COMB: The TADS Team [13]
CDC [14] —
Solomon et al. [15] —
CDC [11] SSRIs: Dubicka et al. [12]
CBT: The TADS Team [13]
COMB: The TADS Team [13]
CDC [14] —
Solomon et al. [15] —
CDC [11] SSRIs: Dubicka et al. [12]
CBT: The TADS Team [13]
COMB: The TADS Team [13]
CDC [14] —
CDC [11] —
ifferent survival distributions used in the model.
nin reuptake inhibitors; CBT, cognitive behavioral therapy; COMB,e m
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well as RRs of suicidal events, over the 36-week trial period
according to the TADS, supplemented with data from the pub-
lished literature regarding risks of recurrence and relapse of
major depressive episodes, background mortality, and fatal or
nonfatal suicidal acts.
In extrapolating beyond the time horizon of empiric data (i.e.,
beyond the 36 weeks of TADS data), we generated several “sce-
nario” analyses, each reflecting different assumptions about long-
term effects of treatment. In the first extrapolation (scenario 2), we
assumed that the suicide attempt risks associated with the treat-
ment strategies do not extend beyond 36 weeks and that the re-
mission rates follow natural history trends beyond 36 weeks, in-
dependent of treatment strategy. In scenario 3, treatment-related
suicide attempt risks and remission rates observed in TADS over
the first 36 weeks after treatment initiation were assumed to per-
sist unabated over the 5-year time horizon for each treatment
strategy.
We also explored the impact of varying several uncertain as-
sumptions, including 1) the RR of suicide attempts associatedwith
SSRI use; 2) the RR of suicide attempts according to the level of
depression symptoms (i.e., episode vs partial symptom relief vs
full symptom relief); 3) the extrapolation approach of remission
rates; and 4) the proportion of responders who fail to fully remit
from a given episode of MDD (i.e., those who experience partial
symptom relief).
Results
Scenario 1: Analysis with TADS and additional data sources
over a 36-week period
Over a 36-week period, combination treatment (SSRIs plus CBT)
provided an additional 2 to 3 symptom-free weeks per patient
compared with either monotherapy (Table 3). This rank ordering
of treatment strategies with respect to symptom-free weeks
seems to be reflective of the estimated remission rates in the early
stage of treatment from the TADS (i.e., over 18weeks of treatment,
the remission rates were the highest for combination therapy
[56%], followed by SSRIs [37%] and then CBT [27%] [10]). With re-
spect to fatal and nonfatal suicide attempts, the use of SSRIs alone
was associated with the highest number of events per 100,000
patients, while CBT was associated with the lowest number of
events: (e.g., an additional 854 nonfatal and 16 fatal suicide at-
tempts per 100,000 patients treated with SSRIs and an additional
83 nonfatal and 1 fatal suicide attempts per 100,000 patients
Table 3 – Impact of different assumptions regarding data e
Scenario Time
horizon
Strategy Symptom-free we
(per patient)
1 36 wk SSRIs 8.5
CBT 7.8
COMB 10.6
2 5 y SSRIs 110.6
CBT 109.8
COMB 113.2
3 5 y SSRIs 104.8
CBT 106.2
COMB 104.6
Note. In scenario 1, analysis is over 36 wk with no data extrapolation
treatment-related suicide attempt risks and remission rates do not ex
treatment-related suicide attempt risks and remission rates persist b
SSRIs, selective serotonin reuptake inhibitors; CBT, cognitive behaviotreated with combination treatment compared with CBT alone).The consistency of these results with findings from the TADS
showing that suicidal events were more common in patients re-
ceiving fluoxetine therapy (14.7%) than combination therapy
(8.4%) or CBT (6.3%) over 36 weeks of treatment [13] demonstrates
that the model works as intended (i.e., model verification or inter-
nal validation).
Scenarios 2 and 3: Analyses with alternative assumptions of
data extrapolation past 36-week period
With respect to symptom-free weeks over a 5-year period, the two
scenarios showed different results. In scenario 2, where treat-
ment-related suicide attempt risks and remission rates did not
extend beyond 36 weeks, combination therapy remained superior
to both SSRIs and CBT alone, with an additional 3 weeks, on aver-
age, spent without symptoms per patient. In scenario 3, where
treatment-related suicide attempt risks and remission rates per-
sisted beyond 36 weeks, CBT was associated with the highest
number of symptom-free weeks, with an additional 1 to 2 symp-
tom-free weeks compared with SSRIs or combination treatment.
With respect to fatal and nonfatal suicide attempts, the use of
SSRIs alone was associated with the highest number of events in
both scenarios, while CBT was associated with the lowest number
of events. For example, in scenario 2, SSRI usewas associatedwith
an additional 2453 nonfatal and 53 fatal suicide attempts per
100,000 patients and combination treatment was associated with
an additional 467 nonfatal and 9 fatal suicide attempts compared
with CBT treatment alone.
Varying the suicide attempt risk associated with the use
of SSRIs
We repeated the analysis for treatment with SSRIs under scenario
2 by using the RR values of suicide attempts that were estimated
from the FDA meta-analysis (RR  1.6 in the analysis assuming
random effects, and RR  1.9 in the analysis assuming fixed ef-
fects) (see Appendix B of Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2012.03.1390) [3]. As expected, the differ-
ential in suicide attempts between SSRI and the other strategies
increased as the relative suicide risk increased. Our model esti-
mated an additional 722 nonfatal and 22 fatal suicide attempts for
SSRIs per 100,000 patients in the scenario expected to be least
favorable to SSRIs (RR 1.9) relative to the scenario expected to be
most favorable to SSRIs (RR  1.6). Symptom-free weeks per pa-
polation.
Fatal suicide attempts
(per 100,000 patients)
Nonfatal suicide attempts
(per 100,000 patients)
26 1404
10 550
11 633
140 6159
87 3706
96 4173
175 8272
65 3111
95 4362
the TADS; in scenario 2, analysis is over 5 y and assumes that the
beyond 36wk; in scenario 3, analysis is over 5 y and assumes that the
d 36 wk.
erapy; COMB, combination.xtra
eks
from
tend
eyontient remained unchanged under both scenarios.
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728 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 4 – 7 2 9Varying the suicide attempt risk for the level of depression
We explored two alternative scenarios of suicide attempt risk for
each level of depression, one representing the upper and the other
the lower bound of the 95% confidence intervals of the hazard
ratios used in the base-case analysis (see Appendix C of Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2012.
3.1390) [17]. Our model estimated an additional 10,400 nonfatal
nd 219 fatal suicide attempts per 100,000 patientswith SSRI treat-
ent by using the elevated values of suicide risk (95% confidence
nterval upper bound) relative to the more conservative scenario
95% confidence interval lower bound).
Varying the extrapolation approach of remission rates
We explored an alternative extrapolation approach of remission
rates under scenario 3 including the last three data points (i.e.,
probabilities observed at 12–36 weeks rather than probabilities in
the base model based on probabilities at 18 and 36 weeks) in cal-
culating the parameter of the exponential model (see panel B of
Figure 2 in Appendix A of Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2012.03.1390). Our model estimated an in-
crease of 6 symptom-free weeks per patient for combination treat-
ment relative to the base-case results, while there were only
marginal changes in symptom-free weeks for SSRIs and CBT alone.
Under this alternative scenario, combination therapy yielded the
highest symptom-free weeks compared with the other treatments.
Varying the proportion of responders who failed to fully
remit (i.e., those who experience partial symptom relief
upon remission)
The analysis was repeated examining the impact of varying the
proportion of responders who fail to fully remit. As the proportion
increased, symptom-free weeks decreased (see Appendix D of
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2012.03.1390). The effect on symptom-free weeks was most
prominent for lower risk ratios. For example, when increasing
from RR  1.0 and RR  2.0, there were an additional 31 to 32
ymptom-free weeks per patient over the 5-year time horizon,
hile between RR  2.0 and RR  4.0, there were also an addi-
ional 31 to 32 symptom-free weeks.
Discussion
By using a disease simulation model to integrate data from the
TADS and the published literature, we found that the use of SSRIs
alone was associated with the highest number of suicide-related
events over a 36-week and 5-year period, while CBT was associ-
ated with the lowest number of events. The substantially higher
number of suicide deaths and nonfatal attempts associated with
SSRI use compared with CBT alone was, in some scenarios, some-
what offset by a marginal increase in symptom-free weeks. These
results were robust when varying uncertain assumptions includ-
ing suicide attempt risk for SSRIs, suicide attempt risks for level of
depression, and the proportion of responders who failed to fully
remit. With respect to symptom-free weeks, the combination
treatment of SSRIs and CBTwas superior to eithermonotherapy in
the short-term (scenario 1) and the long-term when treatment
effects were assumed to not persist (scenario 2); however, when
treatment-related suicide attempt risks and remission rates per-
sisted beyond 36 weeks (scenario 3), CBT was marginally superior
to both SSRIs and combination treatment. These findings suggest
that the optimal long-term treatment strategy in terms of symp-
tom-freeweeks depends on treatment effects over time, for which
little available clinical data exist.
Our model-based projections are consistent with a recent
meta-analysis indicating psychotherapy to bemarginally superior fto second-generation antidepressants in the longer-termmanage-
ment of depressive symptoms [20]. In the present study, the num-
ber of attempted and completed suicides for SSRIs over a 5-year
period when we assumed that treatment benefits did not persist
beyond 36 weeks (i.e., scenario 2) was roughly 12.60 per 1,000 pa-
tient-years (6,299 fatal and nonfatal suicide attempts over 500,000
patient-years). This rate of suicidal acts is low in comparison to
that reported in a community sample of children and adolescents
during SSRI treatment (28.33 per 1,000 patient-years) [21]. A possi-
ble cause for this discrepancy is that children included in the pop-
ulation study by Schneeweiss et al. [21] were, by design, new users
of antidepressants followed for at most 1 year after their index
prescription fill, whereas subjects in our study were followed over
a 5-year time horizon with rates derived from prevalent as well as
incident users. Moreover, many of our subjects were on mainte-
nance therapy for most of the 5-year period. Because index pre-
scriptions are often prescribed at the height of a depressive crisis,
and maintenance treatment is associated with lower risk periods,
it is not surprising that we observed lower rates of suicidal behav-
ior in our cohort.
The outcomes of the model are presented as point estimates
only (e.g., the number of fatal suicide attempts in SSRI-treated
patients in the scenario 2 analysis is 140). Because of the analytic
technique of simulating individual patients in a DES, natural vari-
ability in projected outcomes arises because of random chance. In
our particular analysis, we achieved reliable results whenwe sim-
ulated 1,000,000 individuals in each treatment arm (i.e., variance
0.0001 across 10model runs of 1,000,000 patients for the different
utcomes).
Themajor strength of this studywas the use of state-of-the-art
ethodology to evaluate the trade-off in risks and benefits of
reatment strategies for depression. Decision-analytic modeling
rovides a framework for informed decision making under condi-
ions of uncertainty. Specifically, it allows for exploration of the
ata to expressly examine “what-if” scenarios and determination
f how robust the base-case results are to parameter uncertainty
nd changes in model assumptions. Furthermore, models facili-
ate projection of results beyond the time horizon of clinical trials.
lso, data from future studies can be used to update the parame-
ers and assumptions of this existing disease simulation model.
Our analysis has a number of limitations. First, treatment dy-
amicswere not included in themodel, and as in the clinical trials,
e assumed that patients did not change treatment options over
he 5-year period. To reflect real-world sequences of interven-
ions, the impact of cross-over to other treatment options should
e explored. This limitation is somewhat mitigated, at least in the
ntidepressant arm, by accumulating evidence that antidepressant
ugmentation and cross-over to other pharmacologic treatment op-
ions do not produce differential outcomes [21–23]. Moreover, our
stimatesof treatmenteffect arebasedon intention-to-treatanalysis
f the TADS, mitigating concerns about cross-over. Second, because
f limited data, simplifying assumptionsweremadewith regard to
hemodel structure, and some transitions were not allowed in the
odel. For example, we did not allow patients to move directly
rom partial symptom relief to full symptom relief. One conse-
uence of this assumption is that patients in partial remission can
ransition only to death, suicide attempt, or relapse into a depres-
ive episode. While in partial remission, patients remain at a
igher risk of suicide attempts (hazard ratio 4.20). Omitting this
ransition could therefore imply an overestimation of the time in
artial symptom relief, whichwould result in an overestimation of
uicide attempts. Because RCTs are too small to observe rare
vents such as death by suicide, we estimated the incidence of
uicide death by applying the population-based case-fatality rate
or suicide attempts among the age-/sex-matchedUS general pop-
lation (e.g., 1 of 206 suicide attempts among 15-year-old girls are
atal) [11]. Third, we do not address how to value the risks and
[[
[
[
[
[
[
[
[
[
[
[
[
[
729V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 4 – 7 2 9benefits that are explicitly estimated in the analysis. Expressing
these outcomes by using measures such as quality-adjusted life-
years, commonly employed in cost-effectiveness analysis, could
facilitate balancing these risks and benefits by using a common
metric for informed decision making.
To our knowledge, no previous study has investigated the risks
and benefits of clinically relevant treatment strategies for pediat-
ric MDD beyond the time horizon of available clinical data. By
using a DES model, we leveraged multiple sources of data, dem-
onstrated the consistency of model projections over a 36-week
period compared with the TADS data, and extended the evalua-
tion of relevant strategies to 5 years.We also provide estimates for
the risk of completed suicides, which clinical trials have not been
able to measure given the short study periods and small sample
sizes. The limitations of our study notwithstanding, our findings
suggest that CBT alone offers a safer profile with respect to death
by suicide and nonfatal attempts compared with combination
treatment or SSRIs alone. Any additional benefits of SSRIs, either
alone or in combination with CBT, must be weighed against the
expected increase in suicides.
Future research should consider the costs associated with the
burden of depression, treatment interventions, and nonfatal sui-
cide attempts to determine the cost-effectiveness of depression
treatments, which may be an important consideration by policy-
makers in identifying the optimal approach to managing depres-
sion in children and young adults.
Source of financial support: Department of Health Policy and
Management, Harvard School of Public Health, Boston, MA.
Supplemental Materials
Supplementalmaterial accompanying thisarticle canbe found in the
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